| abstract |
The invention relates to methods, devices and kits for providing prognosis of subjects having lymphoma. In particular, the methods relate to determining likelihood of survival, recurrence or treatment outcome in B-cell lymphoma patients who have undergone and/or undergoing chemotherapy. In particular, the present invention provides a method for providing a prognosis of a subject having diffuse large B-cell lymphoma responding to a treatment regime including an anthracycline and a B-celldepleting antibody, such as an anti-CD20 antibody, the method comprising: determining an immune score for the subject based upon the ratio of a level of any one or more of CD137, CD4, CD8, CD56, TNFα (alpha) and LMO2 in the subject to a level of any one or more of PD-1, PD-L1, CD163, CD68, PD-L2, LAG3, TIM3 and SCYA3(CCL3) in the subject, comparing the immune score to a reference score; wherein the immune score in comparison with the reference score is indicative of the subject's prognosis of responding to a treatment regime including an anthracycline and a B-cell depleting antibody. |